NO20065159L - Mutations in ERB2 that are associated with cancer phenotypes - Google Patents

Mutations in ERB2 that are associated with cancer phenotypes

Info

Publication number
NO20065159L
NO20065159L NO20065159A NO20065159A NO20065159L NO 20065159 L NO20065159 L NO 20065159L NO 20065159 A NO20065159 A NO 20065159A NO 20065159 A NO20065159 A NO 20065159A NO 20065159 L NO20065159 L NO 20065159L
Authority
NO
Norway
Prior art keywords
mutations
erb2
cancer
cancer phenotypes
phenotypes
Prior art date
Application number
NO20065159A
Other languages
Norwegian (no)
Inventor
Michael Stratton
Andrew Futreal
Richard Wooster
Original Assignee
Wellcome Trust
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB0417107.0A external-priority patent/GB0417107D0/en
Application filed by Wellcome Trust filed Critical Wellcome Trust
Publication of NO20065159L publication Critical patent/NO20065159L/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)

Abstract

Det beskrives mutasjoner i ErbB2 genprodukter. Mutasjoner som beskrives er identifisert i humane tumorer av naturlig opprinnelse. Disse mutasjoner er assosiert med canceraktige fenotyper og kan anven des som basis for diagnose av cancer, canceraktige celler eller en predisponering for cancer i menneske, seleksjon av egnet anticancerterapi og for utvikling av anticancer terapeutikum.Mutations are described in ErbB2 gene products. Mutations described are identified in human tumors of natural origin. These mutations are associated with cancerous phenotypes and can be used as a basis for diagnosis of cancer, cancerous cells or a predisposition to human cancer, selection of appropriate anticancer therapy and the development of anticancer therapeutics.

NO20065159A 2004-07-30 2006-11-09 Mutations in ERB2 that are associated with cancer phenotypes NO20065159L (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US59253804P 2004-07-30 2004-07-30
GBGB0417107.0A GB0417107D0 (en) 2004-07-30 2004-07-30 Genes II
PCT/GB2005/002976 WO2006010938A1 (en) 2004-07-30 2005-07-29 Mutations in erb2 associated with cancerous phenotypes

Publications (1)

Publication Number Publication Date
NO20065159L true NO20065159L (en) 2007-04-30

Family

ID=35106874

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20065159A NO20065159L (en) 2004-07-30 2006-11-09 Mutations in ERB2 that are associated with cancer phenotypes

Country Status (7)

Country Link
EP (1) EP1771472A1 (en)
JP (1) JP2008515386A (en)
AU (1) AU2005266133A1 (en)
CA (1) CA2575462A1 (en)
NO (1) NO20065159L (en)
NZ (1) NZ551325A (en)
WO (1) WO2006010938A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2976294B1 (en) * 2011-06-10 2018-02-16 Universite De Nice Sophia Antipolis METHOD FOR PREDICTING THE RESPONSE TO TREATMENT WITH HER2 BLOCKING AGENT
WO2019041045A1 (en) 2017-09-01 2019-03-07 The Hospital For Sick Children Profiling and treatment of hypermutant cancer

Also Published As

Publication number Publication date
AU2005266133A1 (en) 2006-02-02
JP2008515386A (en) 2008-05-15
EP1771472A1 (en) 2007-04-11
CA2575462A1 (en) 2006-02-02
WO2006010938A1 (en) 2006-02-02
NZ551325A (en) 2009-11-27

Similar Documents

Publication Publication Date Title
MX2010005081A (en) Method of determining the probability of a therapeutic response in cancer chemotherapy with cardiac glycoside.
WO2003056036A3 (en) Genes
EP2527466A3 (en) Genetic variants on CHR2 as markers for use in breast cancer risk assessment, diagnosis, prognosis and treatment
MX339822B (en) Phosphoramidate derivatives of 5 - fluoro - 2 ' - deoxyuridine for use in the treatment of cancer.
MX2009012722A (en) Genetic variants on chr 5pl2 and 10q26 as markers for use in breast cancer risk assessment, diagnosis, prognosis and treatment.
GB2467467C (en) TAZ/WWTR1 for diagnosis and treatment of cancer
WO2006133361A3 (en) Use of gene expression profiling to predict survival in cancer patient
NO20082960L (en) Ligands with binding specificity for VEGF and / or EGFR and methods for their use
WO2008089397A3 (en) Adrb2 cancer markers
EP2582847A4 (en) Methods and materials for assessing loss of heterozygosity
WO2008134474A3 (en) Compositions and methods including cell death inducers and procaspase activation
WO2012177595A9 (en) Compositions and methods for the therapy and diagnosis of cancer
WO2008073899A3 (en) Prrg4-associated compositions and methods of use thereof in methods of tumor diagnosis
AU316078S (en) Surgical tissue stimulator/locator
MX2010005057A (en) Methods and compositions for diagnostic use in cancer patients.
WO2006060265A3 (en) Methods and systems for prognosis and treatment of solid tumors
WO2008060945A3 (en) Diagnosis and treatment of breast cancer
WO2008003656A3 (en) Prostate specific transcripts and the use thereof for prostate cancer therapeutics and diagnostics
WO2007116404A3 (en) Cucurbitacin glucosides and use thereof in treating cancer
MX2010003415A (en) An ex vivo, fast and efficient process to obtain activated antigen-presenting cells that are useful for therapies against cancer and immune system-related diseases.
NO20081045L (en) Compounds and Methods for Treating Cancer
HK1116186A1 (en) Azaxanthones and use thereof for treating tumors
BR112013009660A2 (en) fusion protein with activity factor ix
WO2012109233A3 (en) Methods for predicting recurrence risk in breast cancer patients
CY1117701T1 (en) TEMSIRIOLIMUM ACTIVITY AGAINST TUMOR CANCER CELL RADICAL CELLS

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application